Table 3.
Other treatments in addition to CVD
| Responders | Non-responders | |||
|---|---|---|---|---|
| n | Pt no. | n | Pt no. | |
| 2nd OPE | 2 | 4, 8 | 1 | 21 |
| Local radiation | 0 | 2 | 13, 19 | |
| 131I-MIBG | 0 | 1 | 18 | |
| TAE | 0 | 1 | 15 | |
| 2nd OPE + 131I-MIBG | 1 | 10 | 3 | 3, 17, 22 |
| 2nd OPE + local radiation | 0 | 1 | 20 | |
| 2nd OPE + TAE + other neoplastic therapiesa | 1 | 2 | 0 | |
| TAE + local radiation + other neoplastic therapiesb | 1 | 5 | 0 | |
| 2nd OPE + 131I-MIBG + local radiation + other neoplastic therapiesc | 1 | 1 | 0 | |
| TAE + other neoplastic therapiesa | 0 | 1 | 9 | |
| 2nd OPE + TAE + local radiation + other neoplastic therapiesd | 0 | 1 | 12 |
All surgical interventions, including a second operation in six patients, were performed before CVD initiation. Other chemotherapy regimens, including sunitinib performed after CVD, were deemed ineffective. Local radiation for bone metastasis and TAE for hepatic lesions were always performed during/after CVD treatment. 131I-MIBG treatments were administered in two cases (patients 10 and 17) before CVD and in four cases (patients 2, 5, 9, 12, and 15) after CVD
CVD cyclophosphamide, vincristine, and dacarbazine, 2nd OPE second operation, local radiation local external beam radiation therapy, 131 I-MIBG 131I-labeled metaiodobenzylguanidine therapy, TAE transcatheter arterial embolization, Pt no. patient number
aCisplatin + 5-fluorouracil
bSunitinib
cCisplatin + VP-16
dS-1 (tegafur/gimeracil/oteracil potassium) + sunitinib